Arrhythmia: Clinical Trials

2 trials for Arrhythmia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Terminated 2

Follow Arrhythmia: new trials by email Literature Review of Arrhythmia trials Research Report on Arrhythmia

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease
GAP-486 (ZP-123), 0.9% Sodium Chloride, USP - Arrhythmia
Phase 2TerminatedWyeth is now a wholly owned subsidiary of Pfizer902005-11-012007-12-10
Study Evaluating GAP-486 in Heart Rhythm
GAP-486 (ZP-123), 0.9% Sodium Chloride, USP - Arrhythmia
Phase 2TerminatedWyeth is now a wholly owned subsidiary of Pfizer302005-11-012007-12-10

Narrower conditions

Arrhythmias, Cardiac (2)  ·  Syncope (1)

Broader conditions

Cardiovascular Diseases (2)  ·  Heart Diseases (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Consciousness Disorders (1)  ·  Nervous System Diseases (1)  ·  Neurobehavioral Manifestations (1)  ·  Neurologic Manifestations (1)  ·  Signs and Symptoms (1)  ·  Unconsciousness (1)

Interventions

Sodium Chloride (2)  ·  rotigaptide (2)

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer (2)

Countries

Canada (2)  ·  United States (2)